Ipca Laboratories Limited delivered impressive financial performance in Q3FY26, demonstrating strong growth across key business segments. The pharmaceutical company's standalone revenue from operations increased 11% year-on-year to ₹1,845.18 crores, while net profit grew 13% to ₹303.45 crores, reflecting the company's robust operational efficiency and market positioning.

Financial Performance Overview

The company's quarterly results showcase consistent growth momentum across both standalone and consolidated operations. Total income on a standalone basis reached ₹1,863.00 crores, up from ₹1,680.09 crores in Q3FY25.

Segment-wise Revenue Performance

The company demonstrated strong performance across its key business segments, with domestic formulations leading the growth trajectory.

Export performance was particularly noteworthy, with branded exports growing 28% to ₹204.87 crores and generics exports increasing 21% to ₹271.78 crores. However, institutional exports declined 21% to ₹58.31 crores.

Profitability and Margins

The company achieved significant margin expansion during the quarter. Standalone EBITDA margin improved to 26.09% from 24.25% in Q3FY25, while consolidated EBITDA margin increased to 22.15% from 19.87% in the previous year.

Nine-Month Performance

For the nine months ended December 31, 2025, the company maintained strong momentum with standalone revenue growing 10% to ₹5,522.40 crores and net profit increasing 22% to ₹870.23 crores. Consolidated revenue reached ₹7,257.85 crores, up 8% year-on-year.

Management Outlook and Strategic Focus

During the earnings conference call held on February 16, 2026, Managing Director Ajit Kumar Jain highlighted the company's strong market position. The domestic business maintained its 16th rank as per IQVIA with a market share of 2.08% MAT December 2025, outpacing the Indian Pharmaceutical Market (IPM) growth of 8.9% with Ipca's growth of 10.6%.

The management expects continued growth momentum with projected annual growth of 10-12% across key business segments. The company anticipates EBITDA margin improvement of 1.5% annually, driven by higher-margin business growth and operational leverage.

Exceptional Items and Corporate Actions

During the quarter, the consolidated results included a net gain of ₹17.65 crores from the disposal of land and building by subsidiary Unichem Laboratories Limited. The company also completed the acquisition of 100% equity interest in Unichem Laboratories Limited, Ireland, and incorporated a wholly owned subsidiary in Germany.

Regulatory Compliance and Publication

Pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories published its Q3FY26 unaudited financial results in Business Standard and Nav Shakti newspapers on February 14, 2026. The results were approved by the Board of Directors at their meeting held on February 13, 2026.

Future Growth Initiatives

The company continues to focus on expanding its biosimilar portfolio with 5 candidates under development, targeting global markets including the US, Europe, and UK. Technology transfer for two products has commenced, with manufacturing expected to begin shortly. The management also highlighted strong growth in therapeutic segments including pain management (13% growth), cardiovascular (16% growth), and diabetes (14% growth).

Ipca Laboratories Limited has announced the commencement of commercial production at its new greenfield Drug Intermediates and Active Pharmaceutical Ingredients (APIs) manufacturing facility. The company informed the stock exchanges about this significant milestone on February 9, 2026.

Facility Details and Investment

The new manufacturing facility is strategically located at Village Hingani in District Wardha, Maharashtra. The company has invested approximately Rs 182 crores in establishing this greenfield facility, which represents a substantial expansion of its manufacturing capabilities.

Regulatory Compliance and Communication

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was filed through online filing system and addressed to both major stock exchanges where the company's shares are listed.

The disclosure was signed by Harish P. Kamath, Corporate Counsel & Company Secretary (ACS 6792), on behalf of Ipca Laboratories Limited. The digital signature was authenticated on February 9, 2026, at 17:02:15 +05'30'.

Strategic Significance

This new facility enhances Ipca Laboratories' manufacturing footprint in the pharmaceutical sector, specifically focusing on Drug Intermediates and Active Pharmaceutical Ingredients production. The commencement of commercial production marks the successful completion of the facility setup and validation processes, enabling the company to begin revenue generation from this investment.